[放射性免疫疗法在肝细胞癌（HCC）多模态治疗中的评估]

[Evaluation of radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma (HCC)].

作者信息

Li K D

机构信息

Liver Cancer Institute, Shanghai Medical University.

出版信息

Zhonghua Zhong Liu Za Zhi. 1992 Nov;14(6):430-2.

PMID:1338985

Abstract

The evaluation of radioimmunotherapy using 131I-anti HCC isoferritin IgG antibody in the multimodality treatment of HCC was reported. Forty three patients with surgically verified unresectable HCC have been treated by radioimmunotherapy as a part of multimodality treatment during 1985-1990. The short-term responses and prolong survival were compared with that in control group of 39 patients with HCC receiving conventional multimodality treatment. The rates of tumor shrinkage, AFP level decline and second resection in radioimmunotherapy group were 67.4% (29/43), 69.6% (16/23) and 30.2% (13/43) respectively, significantly higher than those in control group 23.1% (15/39), 40.0% (8/20) and 10.3% (4/39) respectively. The 1, 3, 5-year survival rates were 61.5%, 40.4% and 35.5% in radioimmunotherapy group, however, in control group were 51.3%, 20.1% and 15.5%, respectively. The results suggested that radioimmunotherapy is one of modalities of choice, particularly for the treatment of unresectable HCC in the multimodality treatment regimen.

摘要

报道了使用¹³¹I-抗肝癌铁蛋白IgG抗体进行放射免疫治疗在肝癌多模式治疗中的评估情况。1985年至1990年期间，43例经手术证实无法切除的肝癌患者接受了放射免疫治疗作为多模式治疗的一部分。将其短期反应和生存期延长情况与39例接受传统多模式治疗的肝癌对照组患者进行了比较。放射免疫治疗组的肿瘤缩小率、甲胎蛋白（AFP）水平下降率和二次切除率分别为67.4%（29/43）、69.6%（16/23）和30.2%（13/43），显著高于对照组的23.1%（15/39）、40.0%（8/20）和10.3%（4/39）。放射免疫治疗组的1年、3年、5年生存率分别为61.5%、40.4%和35.5%，而对照组分别为51.3%、20.1%和15.5%。结果表明，放射免疫治疗是一种可选择的治疗方式，特别是在多模式治疗方案中用于治疗无法切除的肝癌。